CORT Latest Press Releases

-- February 12, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT PRNewswire 6:56 PM

-- February 9, 2026 --

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm Globe Newswire 10:58 AM

CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm PRNewswire 8:12 AM

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT PRNewswire 4:54 AM

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm PRNewswire 3:38 AM

-- February 5, 2026 --

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm PRNewswire 5:21 AM

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT PRNewswire 4:48 AM

-- February 4, 2026 --

CORCEPT INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Encourages Corcept Therapeutics Investors to Contact the Firm Regarding Ongoing Investigation Globe Newswire 5:10 PM

Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced - Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Business Wire 2:58 PM

-- February 3, 2026 --

Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation Business Wire 4:00 PM

Securities Fraud Investigation Into Corcept Therapeutics Incorporated (CORT) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz Business Wire 3:26 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Corcept Therapeutics Incorporated - CORT Globe Newswire 2:02 PM

-- February 2, 2026 --

CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm PRNewswire 5:46 PM

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT PRNewswire 4:42 AM

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm PRNewswire 4:41 AM

-- January 30, 2026 --

Hagens Berman Investigating Corcept Therapeutics (CORT): Shares Fall After Report That FDA Warned Against Relacorilant Drug Application Filing Business Wire 8:32 PM

Corcept Therapeutics (CORT) Shares Fall Again Amid Report FDA Warned Several Times Not to Submit Relacorilant Drug Application - Hagens Berman Globe Newswire 3:28 PM

Berman Tabacco Announces Investigation of Corcept Therapeutics Incorporated (NASDAQ: CORT) Concerning FDA New Drug Application Globe Newswire 2:20 PM

Rosen Law Firm Encourages Corcept Therapeutics Incorporated Investors to Inquire About Securities Class Action Investigation - CORT Business Wire 12:30 PM

CORCEPT THERAPEUTICS INCORPORATED (NASDAQ: CORT) INVESTIGATION ALERT: Bernstein Liebhard is Investigating Possible Securities Claims against Corcept Therapeutics Incorporated Globe Newswire 11:27 AM

Corcept Therapeutics Investigated for Securities Fraud Following Report of FDA Warnings; Shareholders Should Contact Block & Leviton To Recover Losses Globe Newswire 10:13 AM

-- January 29, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT PRNewswire 10:00 AM

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm PRNewswire 4:30 AM

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT PRNewswire 4:29 AM

-- January 28, 2026 --

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm Globe Newswire 10:00 AM

-- January 27, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT Globe Newswire 1:24 PM

-- January 22, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT PRNewswire 10:00 AM

Overall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer Business Wire 8:00 AM

-- January 21, 2026 --

CORT INVESTIGATION ALERT: Investigation Launched into Corcept Therapeutics (CORT), Hagens Berman Encourages Investors to Contact Firm PRNewswire 6:36 PM

-- January 20, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT Globe Newswire 1:27 PM

-- January 15, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT PRNewswire 10:00 AM

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm PRNewswire 1:29 AM

-- January 14, 2026 --

Corcept Therapeutics Incorporated Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights - CORT Business Wire 9:52 PM

INVESTOR ALERT: Investigation of Corcept Therapeutics Incorporated (CORT) by Holzer & Holzer, LLC Globe Newswire 3:39 PM

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman PRNewswire 11:56 AM

-- January 13, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT Globe Newswire 3:56 PM

-- January 12, 2026 --

CORT Investor ALERT: Corcept Therapeutics Inc. Investigated for Securities Fraud; Investors Should Contact Block & Leviton To Potentially Recover Losses Globe Newswire 11:54 AM

-- January 9, 2026 --

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT) Business Wire 10:00 AM

-- January 8, 2026 --

CORCEPT ALERT: Bragar Eagel & Squire, P.C. is Investigating Corcept Therapeutics Incorporated on Behalf of Corcept Stockholders and Encourages Investors to Contact the Firm Globe Newswire 4:26 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT PRNewswire 10:00 AM

Scott+Scott Attorneys at Law LLP Reminds Investors of Its Investigation Into Corcept Therapeutics Incorporated (NASDAQ: CORT) Globe Newswire 10:00 AM

-- January 7, 2026 --

CORT Investors Have Opportunity to Join Corcept Therapeutics Incorporated Fraud Investigation with the Schall Law Firm Business Wire 8:03 PM

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman Globe Newswire 5:58 PM

-- January 6, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT Globe Newswire 12:53 PM

Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman PRNewswire 12:01 PM

-- December 31, 2025 --

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism Business Wire 8:00 AM

-- November 4, 2025 --

Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update Business Wire 4:05 PM

-- October 28, 2025 --

Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call Business Wire 4:05 PM

-- October 19, 2025 --

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment Business Wire 5:15 AM

-- October 14, 2025 --

Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer Business Wire 8:00 AM

-- September 22, 2025 --

Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 Business Wire 2:30 PM